Minimising surgery and drug intervention
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Roadmap for a National Targeted Skin Cancer Screening Program
Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.
His Majesty King Charles III meets with MIA
We were delighted to have the honour of meeting with His Majesty King Charles III this week, a once-in-a-lifetime opportunity to shine an international spotlight on melanoma.
MIA researchers sharing world stage at ESMO24
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Key next step on the road to zero deaths from melanoma
MIA, alongside ACEMID, hosted an important melanoma data workshop in Sydney, to prepare for the massive volumes of data that will help create the evidence for a national targeted melanoma-screening program.
La Roche-Posay and MIA join forces in fight against skin cancer
La Roche-Posay, the number one skincare brand recommended by dermatologists worldwide, and MIA, world leading melanoma research organisation, have embarked on a new five-year partnership to support critical melanoma research and accelerate awareness of sun safety.
Get on board with sun safety
Announcing a partnership between MIA and the Boating Industry Association (BIA) to promote sun safety amongst boating enthusiasts, including MIA hosting a stand at the Sydney International Boat Show in August.
Preventing disease recurrence in BRAF positive melanoma patients
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
‘Tour of Honour’ for our Australians of the Year
Our 2024 Australians of the Year recently explored the Northern Territory, as part of a visit organised by the Australia Day Council. View the photo album.